Arctigenin induced gallbladder cancer senescence through modulating epidermal growth factor receptor pathway.

about

Arctigenin induced gallbladder cancer senescence through modulating epidermal growth factor receptor pathway.

Item

http://www.wikidata.org/entity/Q38811373

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Arctigenin induced gallbladder ...... rowth factor receptor pathway.

@en

type

Item

label

Arctigenin induced gallbladder ...... rowth factor receptor pathway.

@en

prefLabel

Arctigenin induced gallbladder ...... rowth factor receptor pathway.

@en

P1476

Arctigenin induced gallbladder ...... rowth factor receptor pathway.

@en

P2093

Bin Zuo

http://www.w3.org/2001/XMLSchema#string

Di Zhou

http://www.w3.org/2001/XMLSchema#string

Fei Ma

http://www.w3.org/2001/XMLSchema#string

Jun Liu

http://www.w3.org/2001/XMLSchema#string

Mingdi Zhang

http://www.w3.org/2001/XMLSchema#string

Mingzhe Weng

http://www.w3.org/2001/XMLSchema#string

Shizhong Cai

http://www.w3.org/2001/XMLSchema#string

Shouhua Wang

http://www.w3.org/2001/XMLSchema#string

Wei Gong

http://www.w3.org/2001/XMLSchema#string

Yiyu Qin

http://www.w3.org/2001/XMLSchema#string

P2860

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

Gallbladder Cancer in the 21st Century.

Arctigenin anti-tumor activity in bladder cancer T24 cell line through induction of cell-cycle arrest and apoptosis

Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.

Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy.

Phase II study of erlotinib in patients with advanced biliary cancer.

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

Arctigenin Increases Hemeoxygenase-1 Gene Expression by Modulating PI3K/AKT Signaling Pathway in Rat Primary Astrocytes

MiR-138 Suppresses Cell Proliferation by Targeting Bag-1 in Gallbladder Carcinoma

P304

1010428317698359

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1010428317698359

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28459363

http://www.w3.org/2001/XMLSchema#string